Company Description
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial.
The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jul 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 228 |
| CEO | James Porter |
Contact Details
Address: One Broadway, 14th Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 857-357-7000 |
| Website | nuvalent.com |
Stock Details
| Ticker Symbol | NUVL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1861560 |
| CUSIP Number | 670703107 |
| ISIN Number | US6707031075 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James R. Porter Ph.D. | Chief Executive Officer, President and Director |
| Deborah Ann Miller J.D., Ph.D. | Chief Legal Officer and Secretary |
| Darlene Noci | Chief Development Officer |
| Dr. Christopher D. Turner M.D. | Chief Medical Officer |
| Dr. Benjamin Lane Ph.D. | Chief Technical Operations Officer |
| Dr. Henry Pelish Ph.D. | Chief Scientific Officer |
| Chelcie Lister | Senior Director of Investor Relations and Corporate Communications |
| Matthew Metivier M.B.A. | Senior Vice President of Human Resources |
| John Soglia Ph.D. | Senior Vice President of Translational Development |
| Joshua Horan Ph.D. | Senior Vice President of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2026 | 144 | Filing |
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 144 | Filing |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 24, 2026 | 144 | Filing |
| Mar 12, 2026 | 144 | Filing |
| Mar 6, 2026 | 144 | Filing |